CD8A and breast carcinoma: Furthermore, in syngeneic mouse models of melanoma, sarcoma, colon and breast cancer, Dasatinib administration led to increased CD8+ T cell infiltration, reduced intra-tumoral Treg accumulation, and inhibited tumor growth [141].